Cytomegalovirus Retinitis

Detailed Overview

CMV is a ubiquitous virus that establishes lifelong latency after primary infection. In the setting of profound cellular immunodeficiency (specifically CD4+ T-cell depletion), the virus reactivates and hematogenously spreads to the retina. It causes necrotizing retinitis, presenting with characteristic hemorrhagic and exudative lesions. If left untreated, the progressive necrosis inevitably destroys the macula and optic nerve, or causes retinal detachment, leading to irreversible total blindness. The advent of highly active antiretroviral therapy (HAART) has drastically reduced its incidence.

Epidemiology & Demographics

Historically affected up to 30% of AIDS patients before the HAART era. Currently, incidence in the US is low but remains a significant threat in patients unaware of their HIV status or non-compliant with HAART, specifically when CD4 count falls below 50 cells/microL.

Etiological Mechanism

Reactivation of latent Cytomegalovirus (CMV).

Primary Causes

Untreated or advanced HIV infection with severe CD4 depletion

Iatrogenic immunosuppression following solid organ or hematopoietic stem cell transplantation

• CD4 Count < 50 cells/microL: The absolute most critical risk factor for developing CMV retinitis in HIV+ patients.
• High CMV Viral Load: Systemic CMV viremia correlates with a higher risk of ocular involvement.
• Systemic Immunosuppressants: Prolonged use of high-dose corticosteroids, anti-rejection meds (mycophenolate, tacrolimus), or alemtuzumab.

In severe immunodeficiency, latent CMV in monocytes/macrophages reactivates. The virus reaches the eye via the retinal vasculature. It initially infects the vascular endothelial cells, causing a vasculitis, and then spreads to the glial cells and retinal pigment epithelium (RPE). The virus replicates within these cells, causing cytopathic cell death (necrosis). Because the retina cannot regenerate, the destroyed tissue leaves behind a thin, atrophic glial scar. The active leading edge of infection slowly expands outward. The resultant full-thickness necrosis weakens the retina, making it highly susceptible to rhegmatogenous retinal detachment. Furthermore, immune recovery upon starting HAART can trigger a paradoxically destructive inflammatory response known as Immune Recovery Uveitis (IRU).

Characteristic Clinical Presentation

• Painless Floaters: Often the earliest symptom, described as numerous 'cobwebs' or 'bugs' in the visual field due to vitritis.
• Visual Field Defects: Peripheral blind spots (scotomas) that gradually expand as the necrotic lesion grows.
• Blurred Vision: Occurs early if the macula or optic nerve is involved, or later due to extensive retinal damage.
• Flashes of Light (Photopsia): Suggests retinal traction or impending retinal detachment.

Physical Examination Signs

• Classic 'Pizza Pie' or 'Brushfire' appearance on fundoscopy: Fluffy white perivascular retinal infiltrates with extensive associated retinal hemorrhages.
• Indolent, granular peripheral lesions with less hemorrhage in some cases.
• Minimal to mild anterior chamber inflammation (the eye is typically 'white and quiet' externally).

• Rhegmatogenous Retinal Detachment: Occurs in up to 50% of untreated eyes, driven by the formation of multiple retinal holes in areas of necrotic thinning.
• Immune Recovery Uveitis (IRU): Severe intraocular inflammation occurring weeks to months after starting HAART and CD4 count recovery, causing macular edema.
• Complete Blindness: Inevitable without systemic or intravitreal intervention.

Diagnostic Criteria & Guidelines

Diagnosis is primarily clinical, based on the characteristic fundoscopic appearance (hemorrhage + necrosis) in a severely immunocompromised patient. PCR of aqueous or vitreous fluid for CMV DNA can confirm atypical cases.

Differential Diagnosis

• Toxoplasma Chorioretinitis (typically less hemorrhage, more severe vitritis)
• Syphilitic Uveitis/Retinitis
• Acute Retinal Necrosis (ARN) caused by VZV/HSV (rapidly progressive, severe pain)
• HIV Retinopathy (cotton wool spots alone, non-progressive)

Laboratory Tests & Biomarkers

• CD4+ T-cell Count: Typically < 50 cells/microL in HIV patients.
• Serum CMV PCR: Usually positive for CMV viremia, indicating systemic active infection.
• Aqueous Humor PCR: Highly sensitive and specific for CMV DNA, used if clinical appearance is ambiguous.

Imaging Modalities & Findings

• Dilated Fundus Examination:
• Optical Coherence Tomography (OCT):

• Zone 1 (Sight-threatening)
  Lesions located within 3000 microns of the fovea or 1500 microns of the optic disc. High risk of immediate central vision loss.
• Zone 2
  Lesions extending from Zone 1 to the clinical equator.
• Zone 3
  Peripheral lesions from the equator to the ora serrata.

Second-Line & Adjunctive Therapy

If resistance or toxicity (Valganciclovir causes severe neutropenia): IV Ganciclovir 5 mg/kg every 12h, IV Foscarnet 90 mg/kg every 12h (nephrotoxic), or IV Cidofovir (requires probenecid and saline hydration). Foscarnet or Cidofovir are typically used for UL97-mutant (ganciclovir-resistant) CMV.

Surgical & Procedural Management

Pars plana vitrectomy with endolaser photocoagulation and silicone oil tamponade is required for CMV-associated retinal detachment.

Recommended Lifestyle Changes

• Absolute imperative to initiate and strictly adhere to HAART. Retinitis will not permanently resolve without immune system reconstitution.
• Immediate reporting of any new floaters, flashes, or 'curtain' coming over the vision.

Patient Counseling & Advice

Inform the patient that while medication halts the spread of the virus, the areas of the retina already destroyed cannot regenerate, and any lost vision is permanent. Emphasize that they must stay on maintenance anti-CMV therapy until their CD4 count recovers above 100 on HAART, otherwise the infection will definitely return.

Follow-Up & Monitoring Schedule

Weekly dilated fundus exams by an ophthalmologist during induction, then every 2-4 weeks during maintenance therapy. Routine CBC and CMP to monitor for ganciclovir-induced bone marrow suppression and foscarnet-induced renal failure.

Preventive Strategies

In HIV patients: Early initiation of HAART to prevent CD4 drop. Routine dilated eye exams every 6 months for any patient with CD4 < 50. Primary prophylaxis with oral valganciclovir is no longer routinely recommended due to toxicity, preferring early HAART instead.

Highly dependent on the location of the lesion at the time of diagnosis and the patient's ability to reconstitute their immune system via HAART. Retinitis progression is typically halted within 2 weeks of starting antivirals.